A 16-gene Recurrence Score was found to be significantly predictive of recurrence-free interval and survival in patients with stage I-III clear cell renal cell carcinoma who have undergone nephrectomy.
A reduced estimated glomerular filtration rate (eGFR) was found to be associated with a significantly increased risk for renal and urothelial cancer, according to the results of a recently published study.
High-dose interleukin-2 remains an important treatment for patients with metastatic renal cell carcinoma, producing durable responses even in those patients with chronic renal insufficiency, according to a recent study.
CancerNetwork speaks with Dr. Michael Atkins, who has extensive clinical experience in kidney cancer and development of various new treatments and is presenting this weekend during the renal cancer translational science session at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium.
In this exclusive ASCO podcast, Andrew J. Armstrong, MD, ScM, Assistant Professor of Medicine and Surgery Duke Comprehensive Cancer Center, Departments of Medicine and Surgery, Divisions of Medical Oncology and Urology, addressed the vexing clinical issue of chemotherapy’s limited effectiveness in advanced renal cell carcinoma.